Preview

Clinical Medicine (Russian Journal)

Advanced search

Prediction of comorbid depression in patients with disseminated sclerosis of residents in the northern region

https://doi.org/10.30629/0023-2149-2020-98-3-226-230

Abstract

The mechanism of development of neuropsychological disorders and the assessment of predictors of their development in patients with multiple sclerosis (MS) are insufficiently studied. Prediction of comorbid depression in this category of patients is of great interest and is aimed at personalized medical care for patients with optimal personal and environmental adaptation of the patient with MS.
Objective. To study the predictors of the development of depressive syndrome and to develop a mathematical model for predicting comorbid depression in patients with multiple sclerosis living in the northern region.
Material and methods. A standard neurological examination was conducted in 149 patients with reliable MS who lived in the northern region, including an assessment of the severity of MS disability on the EDSS scale. All patients underwent neuroimaging (magnetic resonance imaging — MRI) of the brain and spinal cord. The Beck Depression Scale was used to identify depressive disorders.
Results. The prevalence of depressive disorders in patients with MS in the studied population of patients in the northern region was 35%. In terms of severity, the identified comorbid depression ranged from subdepression to moderate depression. According to the results of the study, it can be stated that the predictors of the development of comorbid depressive disorders in MS are signs of brain atrophy; chronic intoxication (tobacco smoking and alcohol abuse); foci of demyelination (the semi-oval center, corpus callosum); neurological symptoms in the form of paresis, paralysis, cerebellar symptoms (nystagmus); presence of frontal dysfunction (phonetic associations, selection reactions simple and complicated).
Conclusion. Comorbid depressive manifestations in MS patients living in the northern region occur in 35% of patients and are a multidisciplinary problem. In order to reduce the effect of depressive manifestations on the main symptoms of the disease, adherence to therapy and improve the quality of life indicators in patients with MS, it is necessary to influence neurological symptoms and psychological state, paying special attention to the prevention of depression in these patients.

About the Authors

Zh. I. Molchanova
Khuant-Mansiysk State Medical Academy
Russian Federation
628012, Khanty-Mansiysk


P. B. Tatarintsev
Ugra State University
Russian Federation
628012, Khanty-Mansiysk


M. L. Blagonravov
Russian University of Peoples´Friendship
Russian Federation
117198, Moscow


S. M. Chibisov
Russian University of Peoples´Friendship
Russian Federation
117198, Moscow


O. N. Ragozin
Khuant-Mansiysk State Medical Academy
Russian Federation

Oleg N. Ragozin — MD, PhD, DSc, Professor, Department of Hospital Therapy Khanty-Mansiysk State Medical Academy

628012, Khanty-Mansiysk



References

1. Shmidt T.E. Multiple sclerosis and some other demyelinating disease of the Central nervous system in proceedings of the EFNS Congress (Istanbul, 2014). Nevrologicheskiy zhurnal. 2014;19(5):52–6. (in Russian)

2. Shmidt T.E. Epidemiology, pathogenesis, clinic, differential diagnostics of multiple sclerosis and opticomielit. Nevrologicheskiy zhurnal. 2015;20(1):49–56. (in Russian)

3. Veyn A.M, Voznesenskaya T.G., Vorob’eva O.V. Autonomic disorders: clinical, treatment, diagnosis: a Manual for doctors. Moscow: Meditsinskoe informatsionnoe agentstvo. 2010;640. (in Russian)

4. Shmidt T.E., Yahno N.N. Multiple sclerosis: a guide for doctors 5th edition. M.: MEDpress-inform; 2016;272. (in Russian)

5. Feinstein A. The Neuropsychiatry of multiple sclerosis. Review. Can. J. Psychiatry. 2004;49:674–8.

6. Jongen P., Horst A., Brands A. Cognitive impairment in multiple sclerosis. Minerva Med. 2012;103(2):73–96.

7. Zabad R., Patten S., Metz L. The association of depression with disease course in multiple sclerosis. Neuroligy. 2005;64(2):359–60.

8. Molchanova Zh.I. Correlations between physical and psychological scales of the SF-36 quality of life questionnaire in patients with multiple sclerosis and comorbid depression. Medicinskaya nauka i obrazovanie Urala. 2014;480):15:21–5. (in Russian)

9. Nortvedt M.W., Riise T. et al. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurol. 1999;22(53):1098– 103.

10. Beck А.Т., Ward C.H., Mendelson M., Mock J., Erbaugh J. An Inventory for Measuring Depression. Arch. General Psychiatry. 1961;6(4):561–71.

11. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a frontal assessement battery at bedside. Neurology. 2000;55:1621–6.

12. Folstein M. F., Folstein S.E., McHugh P.R. Mini-Mental State: a practical guidefor grading the mental state of patients for the clinician. J. Psych. Res. 1975;12:189–98.

13. Zaharov V.V., Voznesenskaya T.G. Neuropsychiatric disorders: diagnostic tests. M.: MEDpress-inform. 2013;329. (in Russian)

14. Molchanova Zh. I. Study of comorbid depression in patients with multiple sclerosis living in the Northern region. Ulyanovskii medico-biologichwskii zournal. 2018;3:35–40. (in Russian)


Review

For citations:


Molchanova Zh.I., Tatarintsev P.B., Blagonravov M.L., Chibisov S.M., Ragozin O.N. Prediction of comorbid depression in patients with disseminated sclerosis of residents in the northern region. Clinical Medicine (Russian Journal). 2020;98(3):226-230. (In Russ.) https://doi.org/10.30629/0023-2149-2020-98-3-226-230

Views: 797


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 0023-2149 (Print)
ISSN 2412-1339 (Online)